{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:18:52Z","timestamp":1772165932066,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection (ALND) for assessing axillary lymph node status in clinically node-negative breast cancer patients. However, the approach to axillary surgery after neoadjuvant treatment is still controversial. In the present study, our objective was to predict the pathological nodal stage based on SLNB results and the clinicopathological characteristics of patients who initially presented with clinical N1 positivity but whose disease status was converted to clinical N0 after neoadjuvant chemotherapy (NAC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>After NAC, 150 clinically node-negative patients were included. The relationships between clinicopathologic parameters and the number of positive lymph nodes in SLNBs and ALNDs were assessed through binary\/multivariate logistic regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 150 patients, 78 patients had negative SLNBs, and 72 patients had positive SLNBs. According to the ALND data of 21 patients with SLNB1+, there was no additional node involvement (80.8%), 1\u20132 lymph nodes were positive in 5 patients (19.2%), and no patient had\u2009\u2265\u20093 lymph nodes involved. Following the detection of SLNB1\u2009+\u2009positivity, the rate of negative non-sentinel nodes were 75% in the luminal A\/B subgroup, 100% in the HER-2-positive subgroup, and 100% in the triple-negative subgroup. Patients with a lower T stage (T1-3 vs. T4), fewer than 4 clinical nodes before NAC (&lt;\u20094 vs. \u22654), and a decreased postoperative Ki-67 index (&lt;\u200910% vs. stable\/increase) were included. According to both univariate and multivariate analyses, being in the triple-negative or HER2-positive subgroup, compared to the luminal A\/B subgroup (luminal A\/B vs. HER2-positive\/triple-negative), was found to be predictive of complete lymph node response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The number of SLNB-positive nodes, tumor-related parameters, and response to treatment may predict no additional nodes to be positive at ALND.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12893-024-02500-5","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T07:01:44Z","timestamp":1721372504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prediction of the number of positive axillary lymph nodes according to sentinel lymph node involvement and biological subtypes in patients receiving neoadjuvant chemotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Latif","family":"Yilmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulay","family":"Kus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alper","family":"Aytekin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokmen","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evren","family":"Uzun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokturk","family":"Maralcan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"2500_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.ejso.2008.01.034","volume":"34","author":"IM Van der Ploeg","year":"2008","unstructured":"Van der Ploeg IM, Nieweg OE, van Rijk MC, et al. Axillary recurrence after a tumor-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008;34:1277\u201384. [PubMed: 18406100].","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"2500_CR2","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs no Axillary dissection on 10-Year overall survival among women with invasive breast Cancer and Sentinel Node Metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918\u201326. https:\/\/doi.org\/10.1001\/jama.2017.11470.","journal-title":"JAMA"},{"issue":"12","key":"2500_CR3","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.22.01565","volume":"41","author":"SAL Bartels","year":"2023","unstructured":"Bartels SAL, Donker M, Poncet C, et al. Radiotherapy or surgery of the Axilla after a positive sentinel node in breast Cancer: 10-Year results of the Randomized Controlled EORTC 10981\u201322023 AMAROS trial. Clin Oncol. 2023;41(12):2159\u201365. https:\/\/doi.org\/10.1200\/JCO.22.01565.","journal-title":"Clin Oncol"},{"key":"2500_CR4","unstructured":"https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf Version 4.2023."},{"issue":"Suppl 1","key":"2500_CR5","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.breast.2021.08.018","volume":"62","author":"N Maggi","year":"2022","unstructured":"Maggi N, Nussbaumer R, Holzer L, et al. Axillary surgery in node-positive breast cancer. Breast. 2022;62(Suppl 1):S50\u20133. https:\/\/doi.org\/10.1016\/j.breast.2021.08.018.","journal-title":"Breast"},{"issue":"1","key":"2500_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau C, Osdoit M, Noordaa MVD, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicenter pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(21)00589-1.","journal-title":"Lancet Oncol"},{"issue":"18","key":"2500_CR7","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1200\/JCO.23.00615","volume":"41","author":"M Royce","year":"2023","unstructured":"Royce M, Mulkey F, Osgood C, et al. US Food and Drug Administration expanded adjuvant indication of Abemaciclib in High-Risk early breast Cancer. J Clin Oncol. 2023;41(18):3456\u20137. https:\/\/doi.org\/10.1200\/JCO.23.00615.","journal-title":"J Clin Oncol"},{"issue":"24","key":"2500_CR8","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1200\/JCO.2017.74.0472","volume":"35","author":"I Krop","year":"2017","unstructured":"Krop I, Ismaila N, Andre F, et al. Use of biomarkers to Guide decisions on Adjuvant systemic therapy for women with early-stage invasive breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline focused Update. J Clin Oncol. 2017;35(24):2838\u201347. https:\/\/doi.org\/10.1200\/JCO.2017.74.0472.","journal-title":"J Clin Oncol"},{"key":"2500_CR9","doi-asserted-by":"publisher","unstructured":"Vrabie EM, Alecu M, Cirimbei C et al. The Management of Axillary Lymph Nodes in Breast Cancer - A Retrospective Single-Centre Study. Chirurgia (Bucur). 2021 Mar-Apr;116(2):186\u201392. https:\/\/doi.org\/10.21614\/chirurgia.116.2.186.","DOI":"10.21614\/chirurgia.116.2.186"},{"issue":"1","key":"2500_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10549-023-07104-w","volume":"203","author":"SZ Lim","year":"2024","unstructured":"Lim SZ, Yoo TK, Lee SB, et al. Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2024;203(1):95\u2013102. https:\/\/doi.org\/10.1007\/s10549-023-07104-w.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"2500_CR11","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1001\/jamaoncol.2021.4394","volume":"7","author":"AV Barrio","year":"2021","unstructured":"Barrio AV, Montagna G, Mamtani A, et al. Nodal recurrence in patients with node-positive breast Cancer treated with Sentinel Node Biopsy alone after Neoadjuvant Chemotherapy-A Rare Event. JAMA Oncol. 2021;7(12):1851\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4394.","journal-title":"JAMA Oncol"},{"key":"2500_CR12","doi-asserted-by":"publisher","unstructured":"Montagna G, Mrdutt MM, Sun SX et al. Omission of Axillary Dissection following nodal downstaging with Neoadjuvant Chemotherapy. JAMA Oncol 2024 Apr 25:e240578. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0578. Epub ahead of print.","DOI":"10.1001\/jamaoncol.2024.0578"},{"key":"2500_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jss.2023.08.004","volume":"292","author":"GB Peery","year":"2023","unstructured":"Peery GB, Pak J, Burkbauer L, et al. Omission of Axillary Dissection in Node positive breast Cancer after Neoadjuvant systemic therapy. J Surg Res. 2023;292:247\u201357. https:\/\/doi.org\/10.1016\/j.jss.2023.08.004.","journal-title":"J Surg Res"},{"issue":"3","key":"2500_CR14","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1245\/s10434-020-09073-6","volume":"28","author":"O Kantor","year":"2021","unstructured":"Kantor O, Wakeman M, Weiss A, et al. Axillary Management after Neoadjuvant endocrine therapy for hormone receptor-positive breast Cancer. Ann Surg Oncol. 2021;28(3):1358\u201367. https:\/\/doi.org\/10.1245\/s10434-020-09073-6.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"2500_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s12282-018-00934-3","volume":"26","author":"Z Bi","year":"2019","unstructured":"Bi Z, Liu J, Chen P, et al. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla. Breast Cancer. 2019;26(3):373\u20137. https:\/\/doi.org\/10.1007\/s12282-018-00934-3.","journal-title":"Breast Cancer"},{"key":"2500_CR16","doi-asserted-by":"publisher","unstructured":"Wong SM, Basik M, Florianova L et al. Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer [Internet] Ann Surg Oncol 2020. https:\/\/doi.org\/10.1245\/s10434-020-09211-0.","DOI":"10.1245\/s10434-020-09211-0"},{"key":"2500_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.10.014","author":"S Kahler-Ribeiro-Fontana","year":"2020","unstructured":"Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F, et al. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up [Internet]. Eur J Surg Oncol. 2020. https:\/\/doi.org\/10.1016\/j.ejso.2020.10.014.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"2500_CR18","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1245\/s10434-020-08928-2","volume":"28","author":"MF Almahariq","year":"2021","unstructured":"Almahariq MF, Levitin R, Quinn TJ, et al. Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in breast Cancer patients with residual N1 nodal Disease following neoadjuvant chemotherapy. Ann Surg Oncol. 2021;28(2):930\u201340. https:\/\/doi.org\/10.1245\/s10434-020-08928-2.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2500_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/jso.27241","volume":"128","author":"RE Sargent","year":"2023","unstructured":"Sargent RE, Siegel E, Ito F, et al. Axillary lymph node recurrence following wire-directed sentinel lymph node dissection for breast cancer patients with biopsy-proven axillary metastases prior to neoadjuvant chemotherapy at a safety net medical center. J Surg Oncol. 2023;128(1):9\u201315. https:\/\/doi.org\/10.1002\/jso.27241.","journal-title":"J Surg Oncol"},{"issue":"2","key":"2500_CR20","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1016\/S1470-2045(14)71134-9","volume":"16","author":"L Livi","year":"2015","unstructured":"Livi L, Meattini I. Radiotherapy or surgery for the axilla in node-positive breast cancer? Lancet Oncol. 2015;16(2):e53. https:\/\/doi.org\/10.1016\/S1470-2045(14)71134-9.","journal-title":"Lancet Oncol"},{"key":"2500_CR21","doi-asserted-by":"publisher","first-page":"q58835920973130","DOI":"10.1177\/1758835920973130","volume":"12","author":"U Nitz","year":"2020","unstructured":"Nitz U, Gluz O, Kreipe KK, et al. The run-in phase of the prospective WSG-ADAPT HR+\/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. Ther Adv Med Oncol. 2020;12:q58835920973130. https:\/\/doi.org\/10.1177\/1758835920973130.","journal-title":"Ther Adv Med Oncol"},{"issue":"14","key":"2500_CR22","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Alliance for clinical trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361. https:\/\/doi.org\/10.1001\/jama.2013.278932.","journal-title":"JAMA"},{"issue":"30","key":"2500_CR23","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1200\/JCO.2014.57.8401","volume":"33","author":"JC Boughey","year":"2015","unstructured":"Boughey JC, Ballman KV, Hunt KK, et al. Axillary Ultrasound after Neoadjuvant Chemotherapy and its impact on Sentinel Lymph Node surgery: results from the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol. 2015;33(30):3386\u201393. https:\/\/doi.org\/10.1200\/JCO.2014.57.8401.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2500_CR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1186\/s13063-018-3021-9","volume":"19","author":"G Henke","year":"2018","unstructured":"Henke G, Knauer M, Ribi K, et al. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials. 2018;19(1):667. https:\/\/doi.org\/10.1186\/s13063-018-3021-9.","journal-title":"Trials"},{"key":"2500_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.breast.2021.09.004","volume":"60","author":"WP Weber","year":"2021","unstructured":"Weber WP, Matrai Z, Hayoz S, et al. Tailored axillary surgery in patients with clinically node-positive breast cancer: preplanned feasibility substudy of TAXIS (OPBC-03, SAKK 23\/16, IBCSG 57\u2009\u2013\u200918, ABCSG-53, GBG 101. Breast. 2021;60:98\u2013110. https:\/\/doi.org\/10.1016\/j.breast.2021.09.004.","journal-title":"Breast"},{"issue":"12","key":"2500_CR26","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(14)70460-7.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2500_CR27","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/CCO.0000000000000882","volume":"34","author":"I Meattini","year":"2022","unstructured":"Meattini I, Salvestrini V, Becherini C. Radiation therapy on the axilla after neoadjuvant chemotherapy. Curr Opin Oncol. 2022;34(6):647\u201352. https:\/\/doi.org\/10.1097\/CCO.0000000000000882.","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"2500_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12893-023-02101-8","volume":"23","author":"YJ Fan","year":"2023","unstructured":"Fan YJ, Li JC, Zhu DM, et al. Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: a systematic review and meta-analysis. BMC Surg. 2023;23(1):209. https:\/\/doi.org\/10.1186\/s12893-023-02101-8.","journal-title":"BMC Surg"}],"container-title":["BMC Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-024-02500-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12893-024-02500-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-024-02500-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T07:05:07Z","timestamp":1721372707000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsurg.biomedcentral.com\/articles\/10.1186\/s12893-024-02500-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2500"],"URL":"https:\/\/doi.org\/10.1186\/s12893-024-02500-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3452035\/v1","asserted-by":"object"}]},"ISSN":["1471-2482"],"issn-type":[{"value":"1471-2482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,19]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the research Ethics Committee of Gaziantep University Medical Faculty, approval number (12.07.2023, No:2023\/228). All procedures involving human participants in this study were in accordance with the ethical standards of the institutional research committee and the 1964 Helsinki Declaration. The requirement for written informed consent from each patient was waived owing to the retrospective design of the study by the research Ethics Committee of Gaziantep University Medical Faculty, approval number (12.07.2023, No:2023\/228).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}